Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-13 5:53 pm Purchase | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND L P | 3,833,785 9.98% | 102,041 (+2.73%) | View |
| 2023-01-10 5:21 pm Unchanged | 13D | Viracta Therapeutics, Inc. VIRX | Schindel Yair Chaim | 7,392,237 19.35% | 0 (Unchanged) | View |
| 2022-07-08 4:56 pm Sale | 13G | Viracta Therapeutics, Inc. VIRX | BlackRock Inc. BLK | 542,431 1.4% | -1,826,487 (-77.10%) | View |
| 2022-02-15 1:48 pm Sale | 13G | Viracta Therapeutics, Inc. VIRX | LYTTON LAURENCE W | 255,876 0.7% | -1,342,643 (-83.99%) | View |
| 2022-02-14 1:33 pm Purchase | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND L P | 3,731,744 9.9% | 1,917,436 (+105.68%) | View |
| 2022-02-14 12:14 pm Sale | 13G | Viracta Therapeutics, Inc. VIRX | Aisling Capital IV LP | 288,571 0.77% | -9,811,429 (-97.14%) | View |
| 2022-02-09 5:24 pm Purchase | 13G | Viracta Therapeutics, Inc. VIRX | FORWARD VENTURES V LP | 2,664,790 7.14% | 42,516 (+1.62%) | View |
| 2022-02-04 4:12 pm Purchase | 13G | Viracta Therapeutics, Inc. VIRX | BlackRock Inc. BLK | 2,368,918 6.3% | 248,387 (+11.71%) | View |
| 2021-03-10 9:40 pm Sale | 13D | Viracta Therapeutics, Inc. VIRX | New Enterprise Associates 12 Limited Partnership | 0 0% | -7,789,644 (Position Closed) | View |
| 2021-03-08 5:05 pm Purchase | 13G | Viracta Therapeutics, Inc. VIRX | FORWARD VENTURES V LP | 2,622,274 7.09% | 2,622,274 (New Position) | View |
| 2021-03-05 1:30 pm Unchanged | 13G | Viracta Therapeutics, Inc. VIRX | LVP LIFE SCIENCE VENTURES III L.P. | 3,124,094 8.44% | 0 (Unchanged) | View |
| 2021-03-02 06:14 am Unchanged | 13D | Viracta Therapeutics, Inc. VIRX | Schindel Yair Chaim | 7,392,237 19.98% | 0 (Unchanged) | View |
| 2021-02-16 3:50 pm Sale | 13G | SUNESIS PHARMACEUTICALS INC SNSS | CAXTON CORP | 0 0% | -8,134,926 (Position Closed) | View |
| 2021-02-16 11:06 am Sale | 13G | SUNESIS PHARMACEUTICALS INC SNSS | Ayrton Capital LLC | 0 0% | -10,869,565 (Position Closed) | View |
| 2021-02-16 09:50 am Sale | 13G | SUNESIS PHARMACEUTICALS INC SNSS | CVI Investments Inc. | 0 0% | -8,695,652 (Position Closed) | View |
| 2021-02-16 06:24 am Sale | 13G | SUNESIS PHARMACEUTICALS INC SNSS | Nantahala Capital Management LLC | 0 0% | -8,765,600 (Position Closed) | View |
| 2021-02-12 6:47 pm Sale | 13G | SUNESIS PHARMACEUTICALS INC SNSS | BIOTECHNOLOGY VALUE FUND L P | 1,814,308 9.98% | -9,839,617 (-84.43%) | View |
| 2021-01-07 08:39 am Sale | 13G | SUNESIS PHARMACEUTICALS INC SNSS | SABBY MANAGEMENT LLC | 0 0% | -10,869,565 (Position Closed) | View |
| 2021-01-04 12:35 pm Purchase | 13G | SUNESIS PHARMACEUTICALS INC SNSS | LYTTON LAURENCE W | 1,598,519 8.8% | 1,598,519 (New Position) | View |
| 2020-08-07 2:51 pm Purchase | 13G | SUNESIS PHARMACEUTICALS INC SNSS | Ayrton Capital LLC | 10,869,565 6.65% | 10,869,565 (New Position) | View |